Evaluation of ERCC1 expression for cisplatin sensitivity in human hepatocellular carcinoma

Annals of Surgical Oncology

Volumn 18, Issue 4, 2011, Pages 1204-1211

  Ueda, Shigeru ^a   Shirabe, Ken ^a   Morita, Kazutoyo ^a   Umeda, Kenji ^a   Kayashima, Hiroto ^a   Uchiyama, Hideaki ^a   Soejima, Yuji ^a   Taketomi, Akinobu ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EPIRUBICIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; MITOMYCIN C; SMALL INTERFERING RNA; SUCCINATE DEHYDROGENASE;

ADULT; ARTICLE; CANCER SURVIVAL; CARCINOMA CELL; CHEMOSENSITIVITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; TUMOR VOLUME; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CISPLATIN; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; MALE; MIDDLE AGED; RNA, SMALL INTERFERING; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 79955867544     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-010-1414-4     Document Type: Article

References (34)

1. Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular carcinoma. Oncogene. 2006;25:3866-84. (Pubitemid 43980482)
2. Yamashita Y, Taketomi A, Itoh S, Harimoto N, Morita K, Fukuhra T, Ueda S, Sanefuji K, Sugimachi K, Tajima T, Maehara Y. Phase I/II study of the lipiodolization using DDP-H (CDDP powder; IA-call®) in patients with unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol. 2009 Jun 3. [Epub ahead of print].
3. Kawaoka T, Aikata H, Takaki S, Katamura Y, Hiramatsu A, Waki K, Takahashi S, Hieda M, Toyota N, Ito K, Chayama K. Transarterial infusion chemotherapy using cisplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma. Cardiovasc Interv Radiol. 2009;32:687-94.
4. Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, Sumie S, Yano Y, Okuda K, Sata M. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer. 2002;95(3):588-95. (Pubitemid 34810185)
5. Okuda K, Tanaka M, Shibata J, Ando E, Ogata T, Kinoshita H, Eriguchi N, Aoyagi S, Tanikawa K. Hepatic arterial infusion chemotherapy with continuous low dose administration of cisplatin and 5-fluorouracil for multiple recurrence of hepatocellular carcinoma after surgical treatment. Oncol Rep. 1999;6(3):587-91.
6. Hamabe ST, Yamasaki T, Saeki I, Harima Y, Okita K, Terai S, Sakaida I. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: is the addition of subcutaneous interferon-alpha-2b beneficial? Hepatol Res. 2009;39(3):223-30.
7. Park JY, Ahn SH, Yoon YJ, Kim JK, Lee HW, Lee do Y, Chon CY, Moon YM, Han KH. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer. 2007;110(1):129-37.
8. De Laat WL, Appeldoorn E, Jaspers NG, Hoeijmakers JH. DNA structural elements required for ERCC1-XPF endonuclease activity. J Biol Chem. 1998;273:7835-42. (Pubitemid 28168827)
9. Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV, Lenz HJ. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol. 2001; 19:4298-304. (Pubitemid 33096777)
10. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, Cardenal F, Sanchez JM, Gumerlock PH, Taron M, Sanchez JJ, Danenberg KD, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small-cell lung cancer. Clin Cancer Res. 2002;8:2286-91. (Pubitemid 34753602)
11. Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, Lynch TJ, Su L, Christiani DC. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res. 2004;10:4939-43. (Pubitemid 39099767)
12. Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 expression is a predictor of survival in resected patients with nonsmall-cell lung cancer. Chest. 2005;127:978-83. (Pubitemid 40775532)
13. Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res. 2003;63(6):1311-6. (Pubitemid 36348710)
14. Gossage L, Madhusudan S. Current status of excision repair cross-complementing group 1 (ERCC1) in cancer. Cancer Treat Rev. 2007;33(6):565-77. (Pubitemid 47355341)
15. Liver Cancer Study Group. The general rules for the clinical and pathological study of primary liver cancer. 4th ed. Tokyo: Kanehara Publications; 2000.
16. Wachters FM, Wong LS, Timens W, Kampinga HH, Groen HJ. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer. 2005;50:211-9. (Pubitemid 41427896)
17. Takenaka, T, Yoshino I, Kouso H, Ohba T, Yohena T, Osoegawa A, Shoji F, Maehara Y. Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in nonsmall-cell lung cancer. Int J Cancer. 2007;121:895-900. (Pubitemid 47106222)
18. Takeuchi H, Baba H, Inutsuka S, Takahashi I, Kusumoto H, Maehara Y, Sugimachi K. Antitumor chemosensitivity differs between clinical sarcoma and adenocarcinoma tissues. Anticancer Res. 1994;14:169-71. (Pubitemid 24132107)
19. Oki E, Baba H, Tokunaga E, Nakamura T, Ueda N, Futatsugi M, Mashino K, Yamamoto M, Ikebe M, Kakeji Y, Maehara Y. AKT phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer. 2005;117: 376-80. (Pubitemid 41429560)
20. Itoh S, Taketomi A, Tanaka S, Harimoto N, Yamashita Y, Aishim S, Maeda T, Shirabe K, Shimada M, Maehara Y. Role of growth factor receptor-bound protein 7 in hepatocellular carcinoma. Mol Cancer Res. 2007;5(7):667-73. (Pubitemid 47105485)
21. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002;296:550-3. (Pubitemid 34408678)
22. Sijbers AM, de Laat WL, Ariza RR, Biggerstaff M, Wei YF, Moggs JG, Carter KC, Shell BK, Evans E, de Jong MC, Rademakers S, de Rooij J, et al. Xeroderma pigmentosum group F caused by a defect in a structure-specific DNA repair endonuclease. Cell. 1996;86:811-22. (Pubitemid 26303449)
23. Britten RA, Liu D, Tessier A, Hutchison MJ, Murray D. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer. 2000;89:453-7.
24. Kwon HC, Roh MS, Oh SY, Kim SH, Kim MC, Kim JS, Kim HJ. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol. 2007:18(3): 504-9. (Pubitemid 46359630)
25. Kondo T, Kubota T, Tanimura H, Yamaue H, Akiyama S, Tanigawa N, Kitajima M, Takagi H. Cumulative results of chemosensitivity tests for antitumor agents in Japan. Japan Research Society for Appropriate Cancer Chemotherapy. Anticancer Res. 2000;20:2389-92. (Pubitemid 30614442)
26. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatinbased adjuvant chemotherapy. N Engl J Med. 2006;355(10): 983-91. (Pubitemid 44343542)
27. Fautrel A, Andrieux L, Musso O, Boudjema K, Guillouzo A, Langoët S. Overexpression of the two nucleotide excision repair genes ERCC1 and XPC in human hepatocellular carcinoma. J Hepatol. 2005;43(2):288-93. (Pubitemid 40956882)
28. Andrieux LO, Fautrel A, Bessard A, Guillouzo AL, Baffet G, Sophie L. GATA-1 is essential in EGF-mediated induction of nucleotide excision repair activity and ERCC1 expression through ERK2 in human hepatoma cells. Cancer Res. 2007;67: 2114-23. (Pubitemid 46424230)
29. Tanaka S, Shimada M, Shirabe K, Maehara S, Harimoto N, Tsujita E, Sugimachi K, Maehara Y. A novel intrahepatic arterial chemotherapy after radical resection for advanced hepatocellular carcinoma. Hepatogastroenterology. 2005;52(63):862-5. (Pubitemid 40834621)
30. Niguma T, Mimura T, Tsutui N. Adjuvant arterial infusion chemotherapy after resection of hepatocellular carcinoma with portal thrombosis: a pilot study. J Hepatobiliary Pancreat Surg. 2005;12:249-53. (Pubitemid 40975527)
31. Abe T, Goda K, Futami K, Furuichi Y. Detection of siRNA administered to cells and animals by using a fluorescence intensity distribution analysis polarization system. Nucleic Acids Res. 2009;37 Suppl 7:e56.
32. Gondi CS, Rao JS. Concepts in in vivo siRNA delivery for cancer therapy. J Cell Physiol. 2009;220(2):285-91.
33. Tam KH, Yang ZF, Lau CK, Lau CT, Pang RWC, Ronnie TP. Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma. Cancer Letter. 2009;273:201-9.
34. Wakamatsu T, Nakahashi Y, Hachimine D, Seki T, Okazaki K. The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins. Int J Oncol. 2007;31:1465-72.